JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

89.3 -0.92

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

87.58

Max

91.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+45.43% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.7B

12B

Ankstesnė atidarymo kaina

90.22

Ankstesnė uždarymo kaina

89.3

Naujienos nuotaikos

By Acuity

50%

50%

179 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 00:00; UTC

Svarbiausios naujienos

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026-04-22 23:33; UTC

Uždarbis

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026-04-22 22:40; UTC

Uždarbis

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026-04-22 22:10; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:11; UTC

Uždarbis

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026-04-22 21:01; UTC

Uždarbis

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026-04-22 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026-04-22 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026-04-22 23:16; UTC

Uždarbis

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026-04-22 23:15; UTC

Uždarbis

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026-04-22 22:52; UTC

Uždarbis

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026-04-22 22:51; UTC

Uždarbis

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026-04-22 22:30; UTC

Uždarbis

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026-04-22 22:30; UTC

Uždarbis

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026-04-22 22:29; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026-04-22 22:27; UTC

Uždarbis

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026-04-22 22:06; UTC

Rinkos pokalbiai
Uždarbis

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026-04-22 21:55; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:47; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:37; UTC

Uždarbis

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026-04-22 21:34; UTC

Uždarbis

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026-04-22 21:29; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:20; UTC

Rinkos pokalbiai
Uždarbis

Tesla Expands Manufacturing to Chips -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

45.43% į viršų

12 mėnesių prognozė

Vidutinis 131.41 USD  45.43%

Aukščiausias 175 USD

Žemiausias 90 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

179 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat